BIOPHARMA
By
How Is GSK’s Robust Q2 2025 Growth Powering Next-Gen Specialty Medicines and Vaccine Innovation?
Key Highlights Specialty Medicines Fuel Strong Market MomentumGSK’s specialty portfolio, notably in Respiratory, Immunology & Inflammation (+10%) and…
Pfizer Secures Exclusive Global Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
Key Highlights A Bold Bet on BispecificsIn a significant expansion of its oncology pipeline, Pfizer has obtained exclusive…
Could AbbVie and IGI’s $1.9B Bet on AI-Engineered Trispecific Antibody Signal a New Era for Relapsed Myeloma Treatment?
Key Highlights: AbbVie Accelerates into AI-Powered Immuno-OncologyAbbVie has entered a global licensing agreement worth up to $1.925 billion…
Will AI-Powered Querent™ by Mango Sciences Transform Veeda Lifesciences’ Global Clinical Trial Efficiency?
Key Highlights AI-Driven Precision in Global Trial RecruitmentVeeda Lifesciences, a global CRO, has announced a strategic investment in…
Can Merck’s $3 Billion Restructuring Drive Sustainable Growth Amidst Patent Challenges?
About MerckMerck & Co., Inc. (MSD outside US & Canada) is a global biopharmaceutical company dedicated to innovating…
Is Bristol Myers Squibb’s $300M Immunology Venture with Bain Capital Set to Pioneer Next-Gen Autoimmune Therapies?
Key Highlights About Bristol-Myers SquibbBristol-Myers Squibb is a global biopharmaceutical leader focused on innovative medicines in oncology, immunology,…
